BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 12629125)

  • 1. Influence of body surface area on serum peak thyrotropin (TSH) levels after recombinant human TSH administration.
    Vitale G; Lupoli GA; Ciccarelli A; Lucariello A; Fittipaldi MR; Fonderico F; Panico A; Lupoli G
    J Clin Endocrinol Metab; 2003 Mar; 88(3):1319-22. PubMed ID: 12629125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age influences TSH serum levels after withdrawal of l-thyroxine or rhTSH stimulation in patients affected by differentiated thyroid cancer.
    Montesano T; Durante C; Attard M; Crocetti U; Meringolo D; Bruno R; Tumino S; Rubello D; Al-Nahhas A; Colandrea M; Maranghi M; Travascio L; Ronga G; Torlontano M
    Biomed Pharmacother; 2007 Sep; 61(8):468-71. PubMed ID: 17553654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum thyrotropin (TSH) levels after recombinant human TSH injections in children and teenagers with papillary thyroid cancer.
    Iorcansky S; Herzovich V; Qualey RR; Tuttle RM
    J Clin Endocrinol Metab; 2005 Dec; 90(12):6553-5. PubMed ID: 16174712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of renal function and demographic/anthropomorphic variables on peak thyrotropin after recombinant human thyrotropin stimulation: a stepwise forward multiple-regression analysis.
    Hautzel H; Pisar E; Lindner D; Schott M; Grandt R; Müller HW
    Thyroid; 2013 Jun; 23(6):662-70. PubMed ID: 23136932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age and body composition influence TSH concentrations after administration of rhTSH.
    Holthausen FF; von Müller F; Happel C; Kranert WT; Grünwald F
    Nuklearmedizin; 2015; 54(1):20-5. PubMed ID: 25566749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of human body composition on serum peak thyrotropin (TSH) after recombinant human TSH administration in patients with differentiated thyroid carcinoma.
    Castagna MG; Pinchera A; Marsili A; Giannetti M; Molinaro E; Fierabracci P; Grasso L; Pacini F; Santini F; Elisei R
    J Clin Endocrinol Metab; 2005 Jul; 90(7):4047-50. PubMed ID: 15870133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant thyrotropin use in children and adolescents with differentiated thyroid cancer: a multicenter retrospective study.
    Luster M; Handkiewicz-Junak D; Grossi A; Zacharin M; Taïeb D; Cruz O; Hitzel A; Casas JA; Mäder U; Dottorini ME;
    J Clin Endocrinol Metab; 2009 Oct; 94(10):3948-53. PubMed ID: 19773393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma.
    Mazziotti G; Sorvillo F; Piscopo M; Cioffi M; Pilla P; Biondi B; Iorio S; Giustina A; Amato G; Carella C
    J Bone Miner Res; 2005 Mar; 20(3):480-6. PubMed ID: 15746993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
    Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal.
    Pacini F; Molinaro E; Castagna MG; Lippi F; Ceccarelli C; Agate L; Elisei R; Pinchera A
    J Clin Endocrinol Metab; 2002 Sep; 87(9):4063-8. PubMed ID: 12213846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimum recombinant human thyrotropin dose in patients with differentiated thyroid carcinoma and end-stage renal disease.
    Pitoia F; Ilera V; Zanchetta MB; Foffano A; Niepomniszcze H
    Endocr Pract; 2008 Nov; 14(8):961-6. PubMed ID: 19095593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stimulation test in the follow-up of thyroid cancer: plasma rhTSH levels are dependent on body weight, not endogenously stimulated TSH values.
    Zanotti-Fregonara P; Duron F; Keller I; Khoury A; Devaux JY; Hindié E
    Nucl Med Commun; 2007 Apr; 28(4):257-9. PubMed ID: 17325587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma.
    Pacini F; Molinaro E; Lippi F; Castagna MG; Agate L; Ceccarelli C; Taddei D; Elisei R; Capezzone M; Pinchera A
    J Clin Endocrinol Metab; 2001 Dec; 86(12):5686-90. PubMed ID: 11739420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation?
    Mazzaferri EL; Kloos RT
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1490-8. PubMed ID: 11932270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant Human Thyrotropin Improves Endothelial Coronary Flow Reserve in Thyroidectomized Patients with Differentiated Thyroid Cancer.
    Ippolito S; Ippolito R; Peirce C; Esposito R; Arpaia D; Santoro C; Pontieri G; Cocozza S; Galderisi M; Biondi B
    Thyroid; 2016 Nov; 26(11):1528-1534. PubMed ID: 27558484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic and therapeutic use of recombinant human TSH (rhTSH) in differentiated thyroid cancer.
    Pacini F; Castagna MG
    Best Pract Res Clin Endocrinol Metab; 2008 Dec; 22(6):1009-21. PubMed ID: 19041828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation.
    Tuttle RM; Fleisher M; Francis GL; Robbins RJ
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1737-42. PubMed ID: 11932308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study.
    Taïeb D; Sebag F; Cherenko M; Baumstarck-Barrau K; Fortanier C; Farman-Ara B; De Micco C; Vaillant J; Thomas S; Conte-Devolx B; Loundou A; Auquier P; Henry JF; Mundler O
    Clin Endocrinol (Oxf); 2009 Jul; 71(1):115-23. PubMed ID: 18803678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma.
    Luster M; Lassmann M; Haenscheid H; Michalowski U; Incerti C; Reiners C
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3640-5. PubMed ID: 11061516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Judicious use of recombinant TSH in the management of differentiated thyroid carcinoma.
    Khan MU; Nawaz MK; Shah MA; Syed AA; Khan AI
    Ann Nucl Med; 2010 Oct; 24(8):609-15. PubMed ID: 20700666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.